Medical notice: Educational content only. CanduCardio is intended for healthcare professionals and CanduTV for the general public. It does not replace clinical judgment or professional consultation.
Therapy group: Cardiac myosin activators · Therapy: Omecamtiv mecarbil
In heart failure with reduced ejection fraction, omecamtiv mecarbil modestly reduced the composite of heart failure event or cardiovascular death versus placebo, with no difference in cardiovascular mortality.
Published in N Engl J Med (2021)
Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.
Generated on October 14, 2026
Educational content only. CanduCardio is intended for healthcare professionals and CanduTV for the general public. It does not replace clinical judgment or professional consultation.